SPOTLIGHT: Wyeth sales boosted by Enbrel

Despite major erosion in sales of its heartburn blockbuster Protonix, Wyeth managed to beat Wall Street's expectations for first-quarter earnings, posting a $1.2 billion profit on a 6 percent increase in revenues to $5.71 billion. Protonix sales fell 66 percent, but revenues from the arthritis treatment Enbrel skyrocketed by 36 percent. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.